Related Experiment Videos
Complexed prostate-specific antigen improvement in detecting prostate cancer
1Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4095, USA. okiharaji@hotmail.com
Current Urology Reports
|June 27, 2002
Summary
Complexed prostate-specific antigen (PSA) assays show promise for improving prostate cancer detection. Further research is needed to confirm the variability and clinical utility of these complexed PSA markers.
Area of Science:
- Oncology
- Biochemistry
Background:
- Prostate-specific antigen (PSA) is a key biomarker for prostate cancer.
- Current limitations exist in differentiating benign conditions from prostate cancer using total PSA alone.
- Complexed forms of PSA are being investigated to improve diagnostic accuracy.
Purpose of the Study:
- To review current reports on complexed prostate-specific antigen (PSA) assays.
- To evaluate the potential of complexed PSA for enhancing prostate cancer detection.
- To assess the diagnostic value of different complexed PSA forms.
Main Methods:
- Review of existing literature on complexed PSA assays.
- Analysis of comparative studies involving various PSA markers.
- Evaluation of preliminary data for novel complexed PSA assays.
Main Results:
- Volume-referenced complexed PSA (PSA-ACT and cPSA) may improve prostate cancer detection.
- The additive value of PSA-ACT and cPSA in men with intermediate PSA levels remains debated.
- Emerging assays like PSA-alpha(2)-macrobloblin (PSA-a(2)M) and PSA-alpha(1)-protease inhibitor (PSA-API) show potential.
Conclusions:
- Complexed PSA assays offer a promising avenue for enhanced prostate cancer detection.
- Further studies are required to clarify the variability and clinical application of complexed PSA.
- Novel complexed PSA markers warrant continued investigation for improved diagnostics.